Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

This study is ongoing, but not recruiting participants.

Study NCT00065442 Information provided by Dendreon

First Received: July 23, 2003 Last Updated: March 20, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	November 2010
Estimated Primary Completion Date:	April 2009 (Final data collection date for primary outcome measure)